Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...
In the retrospective validation cohort of 205 patients with PD-L1-High mNSCLC without actionable mutations, patients classified as Onclara IO High had a median overall survival of 484 days, compared ...
Cancer immunotherapy has profoundly changed the therapeutic landscape of several solid tumors, yet only a subset of patients derives durable clinical ...
Cancer immunotherapy has significantly changed the clinical management of multiple malignancies, yet substantial challenges remain in identifying which ...
A novel theranostic approach that targets RET -- a newly identified biomarker for neuroendocrine prostate cancer enables high ...
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP ...
A multimodal artificial intelligence (MMAI)–derived predictive biomarker was trained for long-term (LT) versus short-term (ST) ADT using pretreatment digital prostate biopsy images and clinical data ...
Despite significant advancements in medicine, cancer remains a major health challenge and the leading cause of mortality worldwide, highlighting the urgent need for continued research to identify ...
Patients with pancreatic cancer who have “ultra-low baseline values” of a biomarker used for prognosis have similar survival ...
Researchers at The University of Texas MD Anderson Cancer Center have developed a new computational approach designed to better account for changes in gene expression within tumors relative to their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results